EGFR and non-small cell lung carcinoma: Erlotinib and gefitinib as the first generation of EGFR TKIs and afatinib, neratinib and dacomitinib as the second generation of EGFR TKIs are reversible and irreversible ATP-competitive inhibitors, respectively which have not provided the survival benefits to the patients with EGFR-mutated NSCLC [4, 13–15].